Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc. has notably strengthened its financial position through successful equity financings, resulting in improved financing income of $284K for the recent quarter and $611K year-to-date, an increase from the previous year's $85K and $144K, respectively. The company is preparing for a significant product launch of its LIBERTY Endovascular Robotic Surgical System in the U.S. and Europe, with positive feedback from providers indicating strong market potential and a competitive edge in the minimally invasive surgery segment. Additionally, enhancements to their operational capabilities, including an expanded commercial team and a partnership with a third-party logistics provider, position Microbot Medical for accelerated growth in the coming years, reinforcing a favorable outlook for the company's stock.

Bears say

Microbot Medical Inc faces significant risks that contribute to a negative outlook on its stock, including delays in commercialization and challenges in expanding its device applications into neuro and cardio surgeries. Additionally, the company is grappling with reimbursement headwinds and a lack of profitability in the near term, which may hinder its financial performance and market adoption of its LIBERTY platform. The absence of solid data from randomized controlled trials and potential delays in securing necessary international regulatory approvals further exacerbate the uncertainties surrounding its future growth prospects.

Microbot Medical (MBOT) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.